ReviewCureus2024

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors as Adjunct Therapy to Statins: A New Frontier in Cardiovascular Risk Reduction.

Tasnia Hossain Lamia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.